The legal friction between Danish pharmaceutical giant Novo Nordisk and telehealth provider Hims & Hers has intensified. Even though Hims & Hers announced it would stop selling its compounded version of the semaglutide pill (Wegovy), Novo Nordisk has moved forward with a patent infringement lawsuit.
Retraction by Hims & Hers On February 7, 2026, Hims & Hers stated on X that it would cease offering access to its compounded semaglutide pill. The decision followed “constructive conversations” with industry stakeholders. The company had previously sparked industry-wide debate by promoting affordable weight-loss alternatives through high-profile campaigns, including a 60-second Super Bowl advertisement.
Decisive Action by Novo Nordisk and U.S. Authorities Despite the withdrawal, Novo Nordisk officially filed a lawsuit on February 9, 2026, alleging infringement of its semaglutide patents. Novo’s legal counsel emphasized that the action is necessary to protect intellectual property and ensure public access to FDA-approved, safe, and effective medications.
Simultaneously, the U.S. Department of Health and Human Services (HHS) has referred Hims & Hers to the Department of Justice for investigation into potential violations of the Federal Food, Drug, and Cosmetic Act regarding its mass-compounding practices.
Clashing Perspectives on Healthcare
-
Big Pharma’s Stance: Novo Nordisk is fighting to prevent market erosion in the obesity sector caused by compounded products and competition from Eli Lilly.
-
Hims & Hers’ Stance: The telehealth company criticized the lawsuit as a “blatant attack” on millions of Americans who rely on compounded medications for personalized care, accusing large pharmaceutical firms of weaponizing the judicial system to limit consumer choice.